

Twitter Thread by JST Investments



JST Investments

@JstInvestments



Key insights from Hikal

- Lowered interest rates
- Pharma: Growth in generics as well as CDMO
- Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
- Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals <https://t.co/D70j9oriCa>

Hikal: Strong

\U0001f9ea Rev up 27% YoY

\U0001f9ea 22% EBITDA margin

\U0001f9ea Pat of 50crs

\U0001f9ea Growth across both pharmaceuticals & crop protection. [#Q1withJST](#) [#Pharma](#) pic.twitter.com/8lFo68KzPe

— JST Investments (@JstInvestments) [August 5, 2021](#)